At today's price, JNJ's stock is pricing in about 11% annual free-cash-flow growth for the next ten years. Over the past five years, the company's actual FCF barely moved at all (-0.1% a year), while revenue grew a modest 4.6% a year.
At its current price, JNJ implies ~11.2% annual FCF growth for the next 10 years, discounted at 9%.
JNJ's actual 5-year FCF growth was essentially flat (-0.1%) a year.
Required growth vs. historical growth
Required growth from the reverse DCF below. Historical CAGRs from 10-K FY2021–FY2025. FCF was essentially flat over the period, so its bar is shown as a stub rather than a proportional fill.
Sensitivity: what if the discount rate moves?
| WACC | Required growth |
|---|---|
| 8% | 8.78% |
| 9% (base case) | 11.19% |
| 10% | 13.41% |
| 12% | 17.43% |
Even at the most optimistic discount rate tested (8%), the required growth rate (8.78%) is still far above JNJ's 5-year FCF trend (essentially flat).
What would move this number
- Using FY2025's standalone annual FCF ($19,698M) instead of trailing-twelve-month FCF ($22,244M) would actually raise the required growth rate further, since TTM FCF is higher — meaning the base-case figure (11.19%) is already the more generous of the two.
- Raising the discount rate to an aggressive 12% pushes the required growth rate to 17.4% — a single assumption change that dramatically shifts the picture.
- Switching diluted share count from a 3-month average (2,440.1M) to a 6-month average (2,443.9M) barely moves the result (±0.2 percentage points) — the share-count assumption isn't a weak link in this calculation.
Show your work
Inputs, sources, model assumptions, and the calculation
- Share price$265.77 — Yahoo Finance, Aug 27, 2026 close
- Diluted shares outstanding2,440.1M — 10-Q Q2 FY2026 income statement, 3-month weighted average (period ended Jun 28, 2026)
- Trailing-twelve-month FCF$22,244M — FY2025 FCF ($19,698M) minus 1H2025 FCF ($6,214M) plus 1H2026 FCF ($8,760M)
- Net debt$28,278M — 10-Q Q2 FY2026 balance sheet (Jun 28, 2026): $49,036M total debt minus $20,758M cash
- Discount rate (WACC)9% base case (8%/10%/12% tested)
- Terminal growth rate2.5% — long-run GDP-level assumption
Normalization check: TTM FCF ($22,244M) is +15.5% above the three-year average ($19,262.7M) — within the ±40% threshold, so used as-is without adjustment. Note the TTM figure reflects a large 1H FY2026 operating-cash-flow increase; whether that's durable or one-time requires separate business-level analysis.
Model: free cash flow is assumed to grow at a constant annual rate g for 10 years, then at a 2.5% terminal rate thereafter, solved by bisection for the value of g that equates present value to today's target enterprise value ($676,783M = market cap + net debt).
Historical CAGR check: Revenue CAGR 2021→2025 = ($94,193M ÷ $78,740M)^(1/4) − 1 = 4.58%. FCF CAGR 2021→2025 = ($19,698M ÷ $19,758M)^(1/4) − 1 = -0.08%, essentially flat.
The fine print
- This isn't a fair-value price target — it only shows what the current price already assumes.
- Change the discount rate, the FCF base, the projection window, or the terminal growth rate, and the answer moves — see the sensitivity table above.
- A reverse DCF shows what the market currently expects — it does not say what the stock is "worth."
- Whether 11.2% growth is realistic depends on whether new drugs and MedTech can outrun the Stelara-style patent cliff facing Darzalex and Tremfya — not on this math alone.
- Any investment decision, and its outcome, is your own responsibility.
Frequently asked questions
What growth rate does JNJ's stock price assume?
At today's price, JNJ's stock is pricing in about 11.2% annual free-cash-flow growth for the next ten years, at a 9% discount rate.
How does that compare to JNJ's actual growth?
JNJ's actual FCF was essentially flat over the past five years (-0.1% a year, 2021-2025), and revenue grew a modest 4.6% a year — both far below the 11.2% the current price requires.
What share price was used for this analysis?
This analysis used $265.77, as of the Aug 27, 2026 close.